Novonix (NVNXF) files Form 6-K with Appendix 2A for securities quotation

Rhea-AI Filing Summary

Novonix Limited, an Australia-based foreign private issuer, filed a Form 6-K for October 2025. The filing primarily forwards an attached document, Exhibit 99.1, which is an Appendix 2A Application for quotation of securities dated October 08, 2025.

The report is signed on behalf of Novonix by Chief Financial Officer Robert Long, confirming the company’s submission of this securities quotation application to the market under U.S. reporting rules.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025

001-41208

(Commission File Number)

NOVONIX LIMITED

(Translation of registrant’s name into English)

Level 38

71 Eagle Street

Brisbane, QLD 4000 Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40‑F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT INDEX

Exhibit No.		Description
Exhibit 99.1		Appendix 2A (Application for quotation of securities) dated October 08, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVONIX LIMITED
By:	/s/ Robert Long
	Robert Long
	Chief Financial Officer

Date: October 08, 2025

FAQ

What does Novonix Limited (NVNXF) report in this October 2025 Form 6-K?

Novonix Limited’s October 2025 Form 6-K forwards an Appendix 2A Application for quotation of securities dated October 08, 2025. The filing serves mainly as a cover submission for this exhibit under U.S. securities reporting requirements.

What is Exhibit 99.1 in Novonix Limited (NVNXF) October 2025 Form 6-K?

Exhibit 99.1 is an Appendix 2A Application for quotation of securities dated October 08, 2025. It is listed as the primary exhibit to the Form 6-K, indicating Novonix is seeking quotation of certain securities, though specific amounts are not detailed here.

Who signed the October 2025 Form 6-K for Novonix Limited (NVNXF)?

The Form 6-K is signed by Robert Long, Chief Financial Officer of Novonix Limited. His signature confirms that the company has duly authorized submission of the report and the attached Appendix 2A Application for quotation of securities.

Where is Novonix Limited (NVNXF) headquartered according to this Form 6-K?

Novonix Limited lists its principal executive office at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia. This address identifies the company’s main business location while it files as a foreign private issuer under U.S. securities regulations.

What type of SEC filer is Novonix Limited (NVNXF) in this submission?

Novonix Limited files this report as a foreign private issuer using Form 6-K. The filing notes the company’s status under the Securities Exchange Act, with annual reports made under the foreign issuer framework rather than standard domestic U.S. forms.